Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072373 | 0.91 | LMNA (0.38) | POLBKMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6071835 | 0.90 | MEN1 (0.41) | POLBKMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5784678 | 0.90 | LMNA (0.37) | POLBKMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5786230 | 0.90 | LMNA (0.38) | POLBKMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5784127 | 0.90 | POLB (0.40) | POLBKMT2ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL6072198 | 0.89 | LMNA (0.37) | POLBKMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5784815 | 0.88 | LMNA (0.36) | POLBKMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5786842 | 0.88 | LMNA (0.38) | POLBKMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5784867 | 0.88 | BRAF (0.40) | POLBKMT2ASMN1; SMN2MAPK1NPC1 | |
| SCHEMBL5785643 | 0.87 | LMNA (0.35) | POLBKMT2ALMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | POLB 1887/4885KMT2A 878/4885LMNA 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.